Book contents
- Global Health, Human Rights, and the Challenge of Neoliberal Policies
- Global Health, Human Rights, and the Challenge of Neoliberal Policies
- Copyright page
- Dedication
- Contents
- Book part
- 1 The Right to Health as an Emergent Human Right
- 2 Evaluating Interpretations of the Right to Health
- 3 Health and Human Rights in the Neoliberal Era
- 4 Private Sector Provision, Health, and Human Rights
- 5 Globalization, Health, and Human Rights
- 6 Achieving Improved Access to Medicines
- 7 The Social Determinants of Health, Health Equity, and Human Rights
- 8 Right to Health Perspectives on Universal Health Coverage
- Index
- References
6 - Achieving Improved Access to Medicines
Published online by Cambridge University Press: 05 April 2016
Book contents
- Global Health, Human Rights, and the Challenge of Neoliberal Policies
- Global Health, Human Rights, and the Challenge of Neoliberal Policies
- Copyright page
- Dedication
- Contents
- Book part
- 1 The Right to Health as an Emergent Human Right
- 2 Evaluating Interpretations of the Right to Health
- 3 Health and Human Rights in the Neoliberal Era
- 4 Private Sector Provision, Health, and Human Rights
- 5 Globalization, Health, and Human Rights
- 6 Achieving Improved Access to Medicines
- 7 The Social Determinants of Health, Health Equity, and Human Rights
- 8 Right to Health Perspectives on Universal Health Coverage
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Publisher: Cambridge University PressPrint publication year: 2016
References
Access to Medicines Foundation (2014) The Access to Medicine Index 2014, Haarlem: Access to Medicines Foundation, www.accesstomedicinesindex.org/.Google Scholar
Alkoby, Asher (2012, “Improving Access to Essential Medicines: International Law and Normative Change,” in Forman, Lisa and Kohler, Jillian Clare, eds., Access to Medicines as a Human Right: Implications for Pharmaceutical Industry Responsibility, Toronto, Buffalo, and London: University of Toronto Press, pp. 46–74.CrossRefGoogle Scholar
Babar, Zaheer Ud Din, Ibrahim, Mohamed Izham Mohamed, Singh, Harpal, Burkal, Nadeem Irfan, et al. (2007) “Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia,” PLoS Medicine 4 (3): e82. doi:10:1371/journal.pmed.0040082.CrossRefGoogle ScholarPubMed
Bajaj, Vikas (2012) “India Weighs Providing Free Drugs at State-Run Hospitals,” The New York Times, July 6, Business Day, pp. 1–2.Google Scholar
Beall, Reed and Kuhn, Randall (2012) “Trends in Compulsory Licensing of Pharmaceuticals since the Doha Declaration: A Database Analysis,” PLoS Medicine 9 (1): e1001154.CrossRefGoogle ScholarPubMed
Bigdeli, Maryam, Peters, David H., and Wagner, Anita K. (2014) Medicines in Health Systems: Advancing Access, Affordability and Appropriate Use, Geneva: Alliance for health Policy and Systems Research and the World Health Organization.Google Scholar
Binagwaho, Agnès, Freeman, Richard, Scott, Kirstin, Badrichani, Anne, et al. (2015) “Improving International Accountability – a Tool for Protecting Health as a Basic Human Right,” Health and Human Rights Journal, published online 4/15, www.hhrjournal.org/...impoving-internaGoogle Scholar
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, P., et al. (2009) “Medicine Prices, Availability, and Affordability in 36 Developing and Middle-income Countries: A Secondary Analysis,” The Lancet 373 (9659): 240–249.CrossRefGoogle ScholarPubMed
CESCR (Committee on Economic, Social and Cultural Rights) (2000) General Comment 14: The Right to the Highest Attainable Standard of Health, U.N. Doc. E.C.12.2000.4.EN.Google Scholar
Commission on Intellectual Property Rights (2002) Integrating Intellectual Property Rights and Development Policy: Report of the Commission on Intellectual Property Rights, London.Google Scholar
Congressional Budget Office (2007) Research on the Comparative Effectiveness of Medical Treatments: Issues and Options for an Expanded Federal Role, Washington, DC: U.S. Government, www.cbo.gov/sites/default/files/12-18-comparativeeffectiveness.pdf.Google Scholar
Correa, Carlos M. (2009) “Intellectual Property Rights and Inequalities in Health Outcomes,” in Labonté, Ronald, Schrecker, Ted, Packer, Corrine, and Runnels, Vivien, eds., Globalization and Health: Pathways, Evidence and Policy, New York and Abington, UK: Routledge, pp. 263–288.Google Scholar
Correa, Carlos M. and Matthews, Duncan (2011) The Doha Declaration Ten Years on Its Impact on Access to Medicines and the Right to Health, Discussion Paper, United Nations Development Programme, www.undp.org/...Discussion_P...Google Scholar
Drahos, Peter (2008) “‘Trust Me’: Patent Offices in Developing Countries,” American Journal of Law & Medicine 34: 151–174.CrossRefGoogle ScholarPubMed
Dutfield, Graham (2008) “Delivering Drugs to the Poor: Will the TRIPS Amendment Help?” American Journal of Law & Medicine 34: 07–124.CrossRefGoogle Scholar
Editorial (2013) “What Price Affordable Access?” Nature Biotechnology 31 (6): 467.CrossRefGoogle Scholar
Forman, Lisa (2008) “‘Rights’ and Wrongs: What Utility for the Right to Health in Reforming Trade Rules on Medicines?” Health and Human Rights 10: 37–48.CrossRefGoogle ScholarPubMed
Forman, Lisa and Kohler, Jillian Clare (2012) “Introduction: Access to Medicines as a Human Right – What Does It Mean for Pharmaceutical Industry Responsibilities,” in Forman, Lisa and Kohler, Jillian Clare, eds., Access to Medicines as a Human Right: Implications for Pharmaceutical Industry Responsibility, Toronto, Buffalo, and London: University of Toronto Press, pp. 3–24.CrossRefGoogle Scholar
Gagne, Joshua J. and Choudhry, Niteesh K. (2011) “How Many ‘Me Too’ Drugs Is Too Many?” JAMA 305 (7): 711–712.CrossRefGoogle ScholarPubMed
Gagnon, Marc-André (2013) “Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health,” Journal of Law, Medicine & Ethics 41: 571–580.CrossRefGoogle ScholarPubMed
GAVI the Vaccine Alliance Website 92015) www.gavi.org/.Google Scholar
Global Health Watch (2006) Global Health Watch 2005–2006: An Alternative World Health Report, London: Zed Publishing Company for the People’s Health Movement, Medact, Medico International, Third World Network, Health Action International, and Asociación Latinoamericana de Medicina Social.Google Scholar
Global Health Watch (2009) Global Health Watch 2: An Alternative World Report, London: Zed Publishing Company for the People’s Health Movement, Medact, and the Global Equity Gauge.Google Scholar
Global Health Watch (2014) Global Health Watch 4: An Alternative World Health Report, London and New York: Zed Publishing Company for the People’s Health Movement, Medact, and the Global Equity Gauge Alliance.Google Scholar
Gootendorst, Paul, Hollis, Aidan, Levine, David K., Pogge, Thomas, et al. (2011) “New Approaches to Rewarding Pharmaceutical Innovation,” Canadian Medical Association Journal 183 (6): 681–685.CrossRefGoogle Scholar
Grabowski, Henry G., DiMasi, Joseph A., and Long, Genia (2015) “The Roles of Patents and Research and Development Incentives in Biopharmaceutical Innovation,” Health Affairs 34 (2): 302–310.CrossRefGoogle ScholarPubMed
Grover, Anand (2009) Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, Human Rights Council, A/HRC/11/12.Google Scholar
Grover, Anand (2011) Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, Expert Consultation on Access to Medicines as a Fundamental Component of the Right to Health, Human Rights Council, A/HRC/17/43.Google Scholar
Helfer, Laurence R. and Austin, Graeme W. (2011) Human Rights and Intellectual Property: Mapping the Global Interface, New York and Melbourne: Cambridge University Press.CrossRefGoogle Scholar
Heywood, Mark (2009) “South Africa’s Treatment Action Campaign: Combining Law and Social Mobilization to Realize the Right to Health,” Journal of Human Rights Practice 1 (1): 14–16, doi: 10.1093.CrossRefGoogle Scholar
Hoen, Ellen’t, Berger, Jonathan, Calmy, Alexandra, and Suerie, Moon (2011) “Driving a Decade of Change: HIV/AIDS, Patents and Access to Medicines for All,” Journal of the International AIDS Society 14:15, www.jiasociety.org/content/14/1/15.CrossRefGoogle ScholarPubMed
Hogerzeil, Hans V. (2004) “The Concept of Essential Medicines: Lessons for Rich Countries,” British Medical Journal 329: 1169–1172.CrossRefGoogle ScholarPubMed
Hogerzeil, Hans V. (2006) “Essential Medicines and Human Rights: What Can They Learn from Each Other,” Bulletin of the World Health Organization 84 (5): 371–375.CrossRefGoogle ScholarPubMed
Hogerzeil, Hans V., Liberman, Jonathan, Wirtz, Veronika, Kishore, Sandeep P., et al. (2013) “Promotion of Access to Essential Medicine for Non-communicable Diseases: Practical Implications of the UN Political Declaration,” The Lancet 281: 680–689.CrossRefGoogle Scholar
Human Rights Council (2013) Access to Medicines in the Context of the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, Twenty-third session, agenda item 3, A/HRC/23/L.10/Rev.1.Google Scholar
Hunt, Paul (2008) Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, UN Doc. A/63/263.Google Scholar
Hunt, Paul and Khosla, Rajat (2008) “The Human Right to Medicines,” Sur 5 (8): 99–116.Google Scholar
Hunt, Paul and Khosla, Rajat (2010) “Are Drug Companies Living Up to Their Human Rights Responsibilities? The Perspective of the Former United Nations Special Rapporteur (2002–2008),” PLoS Medicine 7 (9): e1000330.CrossRefGoogle ScholarPubMed
Illingworth, Patricia (2012) “Corporate Social Responsibility and the Right to Essential Medicines,” Forman, Lisa and Kohler, Jillian Clare, eds., Access to Medicines as a Human Right: Implications for Pharmaceutical Industry Responsibility, Toronto, Buffalo, and London: University of Toronto Press, pp. 75–88.CrossRefGoogle Scholar
International Convention on the Elimination of All Forms of Racial Discrimination (1969) United Nations General Assembly Resolution 2106 (XX) of December 21, 1965, Annex 20 U.N. GAOR Supp (No 14) at 47, U.N. Doc. A/6014, entered into force on January 4, 1969.Google Scholar
Jorgensen, Paul D. (2013) “Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda,” The Journal of Law, Medicine & Ethics 4 (3): 561–570.CrossRefGoogle Scholar
Khosla, Rajat and Hunt, Paul (2012) “Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines,” in Forman, Lisa and Kohler, Jillian Clare, eds., Access to Medicines as a Human Right: Implications for Pharmaceutical Industry Responsibility, Toronto, Buffalo, and London: University of Toronto Press, pp. 25–45.CrossRefGoogle Scholar
Koivusalo, Meri and Mackintosh, Maureen (2009) “Global Public Action in Health and Pharmaceutical Policies: Politics and Policy Priorities,” Innovation Knowledge Development Working Paper No. 45, The Open University.Google Scholar
Kulkarni, Kaustubh and Mohanty, Suchitra (2013) “Novartis Loses Landmark India Cancer Drug Patent Case,” Reuters Business and Financial News, www.reuters.com.assets/print?aid=USBRE93002120130401.Google Scholar
Light, Donald W., Lexchin, Joel, and Darrow, Jonathan J. (2013) “Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs,” The Journal of Law, Medicine & Ethics 41: 590–600.CrossRefGoogle ScholarPubMed
Light, Donald W. and Warburton, Rebecca (2011) “Demythologizing the High Costs of Pharmaceutical Research,” BioSocieties, The London School of Economics and Political Science 1745–8552: 1–17.CrossRefGoogle Scholar
Malpani, Rohit and Kamal-Yanni, Mohga (2006) Patents versus Patients: Five Years after the Doha Declaration, Oxfam International, Oxfam Briefing Paper 95.Google Scholar
MDG Gap Task Force Report (2008) Delivering on the Global Partnership for Achieving the MDGs, New York: United Nations Publications.Google Scholar
MDG Gap Task Force Report (2009) Strengthening the Global Partnership for Development in a Time of Crisis, New York: United Nations Publications.Google Scholar
MDG Gap Task Force Report (2012) The Global Partnership for Development: Making Rhetoric a Reality, New York: United Nations Publications.Google Scholar
MDG Gap Force Report (2013) The Challenges We Face, New York: United Nations Publications.Google Scholar
Médecin Sans Frontières (MSF) (2015) Website: The Access Campaign, www.msfacess.org/TheAccessCampaign.Google Scholar
Media Centre (2014) Hepatitis C, fact sheet no. 164, Geneva: World Health Organization.Google Scholar
Media Centre (2015) “WHO Moves to Improve Access to Lifesaving Medicines for Hepatitis C, Drug-resistant TB and Cancers,” Geneva: World Health Organization, www.who.int/mediacentre/news/releases/2015/new-essential-medicines-list/en/.Google Scholar
Mossialos, Elias, Wenzl, Martin, Osborn, Robin, and Anderson, Chloe, eds. (2015) International Profiles of Health Systems, 2014, New York: Commonwealth Fund.Google Scholar
Nagarajan, Rmea (2015) “Free Drugs Plan Gets a Quiet Burial,” Times of India, http://timesof india.com/india/free-drugs-plam-gets-a-quiet-burial/articleshow/4680931.com.Google Scholar
Oke, Emmanuel Kolawole (2013) “Incorporating a Right to Health Perspective into the Resolution of Patent Law Disputes,” Health and Human Rights 15 (2): 97–107.Google ScholarPubMed
Ollove, Michael (2014) “Could New Hepatitis C Drugs Bust State Budgets?” USA Today, March 3, www.usatoday.com/story/news/nation/2014/03/03/stateline-hepat...Google Scholar
Perrone, Matthew (2014) “Soaring Drug Prices Draw Senate Scrutiny,” Associated Press, November 20, www.sanders.semate.gpv/newsroom/must-read/soaring-generic-d...Google Scholar
PLoS Medicine Editors (2010) “Drug Companies Should Be Held More Accountable for Their Human Rights Responsibilities,” PLoS Medicine 7 (9): E1000344.Google Scholar
Reidenberg, Marcus M. and Walley, Tom (2004) “Commentary: The Pros and Cons of Essential Medicines for Rich Countries,” British Medical Journal 329: 1172.CrossRefGoogle ScholarPubMed
Ritter, Geralyn (2010) “Are Drug Companies Living Up to Their Human Rights Responsibilities: The Merck Perspective,” PLoS Medicine 7 (9): el000343.CrossRefGoogle ScholarPubMed
Rodwin, Marc A. (2013) “Introduction: Institutional Corruption and the Pharmaceutical Industry,” The Journal of Law, Medicine & Ethics 41: 544–552.CrossRefGoogle Scholar
Ruggeri, Kai and Nolte, Ellen (2013) Pharmaceutical Pricing: The Use of External Reference Pricing, Rand Europe, www.rand.org.Google Scholar
Shah, Anup (2014) “Foreign Aid for Development Assistance,” Global Issues, www.globalissues.org.Google Scholar
Silverman, Ed (2014) “Will Gilead’s Hepatitis C Drug Bust State Budgets?” WSJ Pharmalot, July 17, http://blogs.wsj.com/pharmalot/2014/07/17/will-gileads-hepatitis-c-dr...Google Scholar
Statista, (2015) The Statistics Portal, www.statista.com/topics/1764/global-pharmaceutical-industry/Google Scholar
United Nations Development Group (2003) Indicators for Monitoring the Millennium Development Goals, New York: United Nations.Google Scholar
United Nations Human Rights Council (2013) Access to Medicines in the Context of the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, A/HRC/23/L.10/ Rev.1.Google Scholar
UNITAID (2014) The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health, Geneva: UNITAID Secretariat, www.unitaid.eu.Google Scholar
WHO/UNICEF (1978) Primary Health Care: Report of the International Conference on Primary Health Care, Alma-Ata, USSR, September 6–12. Health for all, series 1: Geneva: World Health Organization.Google Scholar
World Health Organization (n.d.) Access to Affordable Essential Medicines. www.who.int/medicines/.../MDG08ChapterE...Google Scholar
World Health Organization (2003) The Selection and Use of Essential Medicines,” Report of the WHO Expert Committee 2002.Google Scholar
World Health Organization (2004) What Are Essential Medicines? www.who.int/topic/essential_medicines/en/l.Google Scholar
World Health Organization (2008) WHO Medicines Strategy 2008–2013, working draft. www.who.int/medicines/publications/medicines_strategy.Google Scholar
World Health Organization, Health Action International (2003) Medicine Prices – a New Approach to Measurement, Geneva: World Health Organization, http://whqlibdoc.who.int/hq/2003/WHOEDMPAR2003.2.pdf.Google Scholar
World Trade Organization (1994) Agreement on Trade-Related Aspects of Intellectual Property Rights, 1869 U.N.T.S. 299.Google Scholar
World Trade Organization (2001) Ministerial Conference Fourth Session, Doha, November 9–14, Declaration on the TRIPS Agreement and Public Health, T/MIN(01)/DEC/2.Google Scholar
World Trade Organization (2013) “Responding to Least Developed Countries’ Special Needs in ip,” www.wto.org/english/tratop-?e/trips._e/ldc/e.htm.Google Scholar